RxDoctor Payments Data

Craig Pannell, APRN

Psychiatric/Mental Health · Fort Worth, TXNPI 1013925460

Payments from drug & device makers

$6,016in general payments, 2019–2025

Across 391 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$708
  • Teva Pharmaceuticals USA, Inc.$655
  • Alkermes, Inc.$631
  • Johnson & Johnson$526
  • Indivior Inc.$456
  • plus $2K from 8 others

What the payments were for

  • Food & beverage$5,78696%
  • Education$2304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,016 in reported general payments places this provider in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$12,786
Medicare patients
39
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate42$347,252
Austedo XrDeutetrabenazine15$174,748
Invega TrinzaPaliperidone Palmitate15$153,959
Invega SustennaPaliperidone Palmitate53$129,367
LybalviOlanzapine/Samidorphan Malate48$76,363
VraylarCariprazine Hcl30$42,112
FanaptIloperidone21$34,460
Divalproex Sodium ErDivalproex Sodium110$9,146
BelsomraSuvorexant17$7,689
Olanzapine215$5,264
Paliperidone ErPaliperidone27$4,947
Doxepin Hcl92$4,047
Fluphenazine Hcl13$3,486
Aripiprazole67$3,328
Quetiapine Fumarate186$3,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$708$347,25242 claims
Johnson & JohnsonInvega Trinza, Invega Sustenna$526$283,32668 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Loxapine$655$175,29141 claims
Alkermes, Inc.Lybalvi$631$76,36348 claims
AbbVieVraylar$1,095$42,11230 claims
Vanda Pharmaceuticals Inc.Fanapt$381$34,46021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →